
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
Preparing your cell culture process for scale up from the start can reduce the risk of delays, mitigate costs and rapidly deliver life-changing therapeutics to patients.







